POS1363 THE VALIDITY AND RELIABILITY OF THE TURKISH VERSION OF BEHÇET’S SYNDROME OVERALL DAMAGE INDEX IN A RETROSPECTIVE COHORT

Autor: Y. Yagiz Ozogul, Y. Ozguler, D. Ucar, U. Uygunoglu, Z. Kutlubay, V. Hamuryudan, G. Hatemi
Rok vydání: 2022
Předmět:
Zdroj: Annals of the Rheumatic Diseases. 81:1020.2-1021
ISSN: 1468-2060
0003-4967
Popis: BackgroundBehçet’s syndrome Overall Damage Index (BODI) is a newly developed damage index specific to Behçet syndrome (BS).ObjectivesWe aimed to evaluate validity, reliability and feasibility of the Turkish version of BODI and evaluate its performance for use in retrospective cohort studies for different phenotypes of BS.MethodsThe study included 295 patients with at least 3 visits at 6 months intervals out of 590 consecutive BS patients who were admitted between January 2015 and August 2017. Turkish version of the BODI form was developed by translating into Turkish and backwards by 2 people. BODI scores were calculated for each year during the follow-up period. The test-retest reliability of BODI was assessed by scoring the same 50 patients at 6-month intervals by the same observer (YYO). Two different observers (YYO- YO) assessed the same 50 patients for inter-observer agreement. The intra-class correlation coefficient (ICC) was used to assess the inter and intra-observer agreement. We also evaluated the median time to fill out the form in patients with different types of involvements.ResultsAmong the 295 (158 F/137 M) patients, mean age was 39 (9.9) and the mean disease duration was 8.8 (5.9) years. Clinical features of BS patients were summarized in the Table 1. BODI median score was 1 (IQR=0-1). We observed an increase in BODI score in 111 (38%) patients during follow-up. The main reasons for increasing BODI scores were eye, vascular and neurological involvement (Table 1). The mean ICC for inter-observer agreement was 0.94 (95% CI, 0.89-0.96) and for intra-observer agreement was 1. The median (range) time to complete the form was 2 (1-8) minutes.Table 1.Clinical features and BODI scores of Behçet syndrome patients.Oral ulceration99.7Genital ulceration81.3Erythema nodosum57.1Papulopustular lesions89.5Joint involvement25.2Ocular involvement47.3Vascular involvement21.4Neurologic involvement3.1Gastrointestinal involvement2.7N of patients with more than 3 BODI scores*(%)194 (66)Causes for increase in BODI score**(n=111) (%)Ocular involvement77 (69)Vascular involvement17 (15)Neurological involvement8 (7)Gastrointestinal involvement3 (3)Mucocutaneous inv.6 (5)Cardiovascular inv.1 (0.9)Diabetes mellitus4 (4)Avascular necrosis2 (2)Osteoporosis related fracture1 (0.9)*All patients had at least 3 BODI scores,**Some patients had more than 1 type of involvementConclusionThis study showed that the Turkish version of BODI was a reliable and feasible instrument that could capture the change over time in damage, and could be used in retrospective cohort studies. Ocular involvement was the most common cause of progressive damage in this cohort.Disclosure of InterestsYeliz Yagiz Ozogul: None declared, Yesim Ozguler Speakers bureau: Yesim Ozguler has received honorariums for presentations from UCB Pharma, Novartis, and Pfizer., Didar Ucar: None declared, Ugur Uygunoglu: None declared, Zekayi Kutlubay: None declared, Vedat Hamuryudan Speakers bureau: Vedat Hamuryudan has served as a speaker for AbbVie, Celgene, Novartis, and UCB Pharma., Grant/research support from: Vedat Hamuryudan has received grant/research support from Celgene, Gulen Hatemi Speakers bureau: Gulen Hatemi has served as a speaker for AbbVie, Celgene, Novartis, and UCB Pharma., Grant/research support from: Gulen Hatemi has received grant/research support from Celgene.
Databáze: OpenAIRE
Externí odkaz: